Eli Lilly Launches New Obesity Drug Zepbound in U.S. Pharmacies
INDIANAPOLIS, IN – Pharmaceutical giant Eli Lilly announced the availability of its new obesity treatment, Zepbound, in U.S. pharmacies. The drug, priced at $550 monthly for uninsured patients, is half its list…
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
(Reuters) – Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can…
Lilly experimental ‘triple G’ obesity drug leads to 24.2% weight loss in trial
By Deena Beasley (Reuters) -Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to weight loss of up to 24.2% after…
Experimental Lilly pill, Mounjaro both lead to 15% weight loss in clinical trials
By Deena Beasley (Reuters) -In a mid-stage trial, the highest dose of Eli Lilly’s experimental pill orforglipron led to 14.7% weight loss after 36 weeks for people who were obese or overweight,…
Eli Lilly to invest additional $1.6 billion in 2 new plants
(Reuters) – Eli Lilly and Co said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing of its…
Fake account shows ‘challenges’ with Twitter – Lilly CEO (Nov 16)
(Removes reference to Ricks’ comment on apology from Lilly in paragraph 3) (Reuters) -Eli Lilly & Co Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter account incident…
Analysis-Alzheimer’s drug breakthrough big boost for Roche, Eli Lilly
By Natalie Grover LONDON (Reuters) – The results of a key Alzheimer’s drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal…
Breaking News
